SkinVision App Review: Can an App Check a Mole?

SkinVision is a CE-marked medical app, certified in the EU as a Class IIa device, that photographs one skin spot and gives an instant high- or low-risk indication for the most common skin cancers, plus advice on whether to see a doctor. Independent studies show it misses some cancers and flags many harmless spots. It isn't offered in the US or Canada, and it never replaces a skin exam.

Below we cover how a SkinVision check works, what the published accuracy studies found (including the ones the company didn't run), who the app isn't designed for, what it costs as of October 2026, and the warning signs that mean you should book a dermatologist no matter what any app says. We did not test SkinVision ourselves; this review is based on its official documents and peer-reviewed research.

Is there a better alternative?

That depends on what you want. If you're after a read on your overall skin, such as hydration, pores, texture, tone and visible aging, along with a routine and an ingredient check matched to your skin type, Pori is built for that. It's an iPhone app that turns a selfie into a 0–100 skin score in about 10 seconds, and its ingredient scanner (Pro) flags each ingredient as beneficial, use with caution or avoid for your skin type. Pori is a cosmetic tool. It doesn't diagnose anything and it doesn't check moles.

For a mole you're worried about, the real alternative to SkinVision is a dermatologist. If you want to keep a photo record of your moles between visits, compare the options in our guide to the best mole checking apps and what they can't tell you.

How does a SkinVision check work?

You photograph one spot at a time, and the app's algorithm compares it with the skin cancer images in its database. According to SkinVision's Instructions for Use (revision 1.8, issued June 2026), a "Smart Check" goes like this:

1. Find even lighting without shadows, open the app and tap the body map where the spot is.
2. Hold the phone 4 to 8 inches (10 to 20 cm) from the spot. The camera takes the photo automatically once three checks pass: "In focus," "Detected" and "Clear."
3. Say whether the spot has any symptoms: itching, bleeding, changing or infected.
4. Get a risk indication with a recommendation to keep self-monitoring or to see a healthcare professional.

The outcomes and what the app tells you to do with them:

SkinVision's website adds that when more certainty is needed, a photo "may be reviewed by a panel of real dermatologists." The app also has a body map, check reminders, a downloadable PDF report you can bring to your doctor, a skin cancer risk questionnaire and UV index alerts.

One limit matters a lot for mole tracking. The IFU says the algorithm "does not analyze changes between photos and the photos cannot be overlaid for comparison." Each check stands alone, so you have to spot the change yourself. The same document warns that photos taken in quick succession of the same spot can return different risk outcomes, and tells you to err on the side of caution and see a professional when that happens.

Is SkinVision a medical device?

Yes, in Europe. SkinVision's App Store listing describes it as "a regulated medical device with European CE marking (EU MDR Class IIa)," and the IFU calls it an over-the-counter mobile medical application meant for laypeople. That same IFU says the service "does not diagnose skin cancer" and "is not an alternative to healthcare professionals."

A CE mark tells you a device met EU requirements for its intended use. It doesn't tell you how often the app is right in everyday hands. The authors of a 2020 systematic review in the BMJ went further and argued that the current CE-marking process does not adequately protect the public when it comes to these apps.

The App Store listing also says the app "is not intended for use in the United States and Canada" and is not for anyone under 18. US readers searching for SkinVision should know that American regulators have acted against mole apps before: in 2015 the Federal Trade Commission settled with marketers of two apps, MelApp and Mole Detective, that rated moles low, medium or high risk without adequate scientific evidence.

Is SkinVision accurate?

It's moderately accurate, and the figures depend heavily on who ran the study and how. Two terms help here. Sensitivity is the share of real cancers the app flags as high risk; a miss is a false reassurance. Specificity is the share of harmless spots it correctly calls low risk; a miss is a false alarm and an extra appointment.

A few details in these papers are worth knowing before you trust a result:

• The 95% headline figure comes from a retrospective study. Researchers from the Universities of Birmingham and Nottingham published a letter titled "Sensitivity and specificity of SkinVision are likely to have been overestimated."
• In the Sangers study, sensitivity was higher on an iPhone than on an Android phone (91.0% vs 83.0%). Specificity was 80.1% on benign control lesions but only 45.5% on lesions that already looked suspicious, so more than half of the worrying-but-harmless spots were flagged as high risk. The authors called the accuracy "far from perfect" and asked for a further study focused on suspicious pigmented lesions.
• The Swiss study looked at exactly those pigmented lesions in people at high risk of melanoma. The authors concluded the app "was not as reliable as previously advertised" and warned about over-detection. Only 8.8% of the dermatologists rated the app trustworthy, and no patient preferred an assessment by the app alone.
• The BMJ review concluded that current algorithm-based apps "cannot be relied on to detect all cases of melanoma or other skin cancers."

SkinVision's own figures are more upbeat. Its IFU claims over 90% sensitivity for melanoma, squamous cell carcinoma and basal cell carcinoma and 89% specificity measured on its own user population, and its clinical research page lists the Sangers study as 86.9% sensitivity and 80.1% specificity. That 80.1% is the figure for benign control lesions; the paper's overall specificity was 70.4%. For more on why app accuracy numbers vary so much, see is AI skin analysis accurate.

Who shouldn't rely on SkinVision?

The IFU lists situations where you shouldn't use the app at all. It advises against photographing a spot that:

• is on darker skin types (Fitzpatrick IV, V and VI), "due to camera limitations," or is close in color to the surrounding skin;
• sits under a nail, near a scar, on the lips or genitals, or on or near a skin fold such as the eyelid or navel;
• is surrounded by a rash, multiple spots, or broken skin such as sores, scabs or bleeding;
• has tattoo ink, marker, sunscreen, cream or powder on it, or is covered by a lot of hair.

The darker-skin exclusion is a big one. The AAD notes that in people of African descent, melanoma tends to develop on the palm, the bottom of the foot, or under or around a nail, which are hard places to photograph and, in the case of nails, places the app excludes. Our explainer on AI skin analysis on darker skin tones covers why cameras and training data struggle here.

The IFU also tells people at elevated risk to seek professional care for any worrying spot: anyone with a personal history of skin cancer, a parent, sibling or child with melanoma, red hair, a weakened immune system (for example after an organ transplant), or conditions such as xeroderma pigmentosum or albinism. If that's you, a dermatologist should be your first stop.

How much does SkinVision cost?

SkinVision sells single checks and plans, and some European insurers cover it (the website's pricing section opens with "Not covered by your insurer?"). Prices as of October 2026:

Prices come from the SkinVision website and the UK App Store listing, where the app is rated 4.6 out of 5 from about 2,300 ratings. Prices vary by country and change over time. There is no US price because the app isn't intended for US users.

When should you see a dermatologist instead of using an app?

See a dermatologist, or your GP in the UK, whenever a spot shows a warning sign, whatever an app says. The American Academy of Dermatology's ABCDE rule is the standard checklist:

• A, asymmetry: one half of the spot is unlike the other half.
• B, border: irregular, scalloped or poorly defined edges.
• C, color: varying colors, including tan, brown, black, white, red or blue.
• D, diameter: melanomas are usually larger than 6 mm (about a pencil eraser) when diagnosed, but they can be smaller.
• E, evolving: the spot looks different from the rest or is changing in size, shape or color.

The AAD also says to get checked for a new spot that looks different from your others, or one that itches or bleeds. The NHS adds moles that are painful, inflamed or crusty, and new skin marks that haven't gone away after a few weeks. In England, if a GP suspects melanoma you should be seen by a specialist within 2 weeks.

A low-risk result from SkinVision is no reason to cancel an appointment for a spot that worries you. False negatives happen, and the company's own instructions say regular check-ups remain essential. For how apps and clinicians divide the work, read AI skin analysis vs a dermatologist.

Verdict: is SkinVision worth it?

SkinVision is one of the few consumer mole apps with real regulatory status and published research, and that counts for something. It can nudge you to book an appointment you'd otherwise put off, and its body map, reminders and PDF report help you organize what you show your doctor. Its weaknesses are just as documented: accuracy drops on the suspicious pigmented spots people most want checked, it tends to over-flag, it's not designed for darker skin types, it doesn't compare photos over time, and it isn't available in the US or Canada.

If you live where it's offered and you're an adult with lighter skin, it's a reasonable prompt for action, used alongside self-exams and regular dermatology visits. Treat a high-risk result as a reason to book an appointment and a low-risk result as no guarantee of anything.